Product Description
TrkA inhibitor
Mechanisms of Action: TRKA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Pain|Osteoarthritis, Knee|Low Back Pain
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02136316 |
MAD | P1 |
Completed |
Healthy Volunteers |
2015-11-01 |
2019-03-20 |
Treatments |
|
NCT01981928 |
7962-CL-0001 | P1 |
Completed |
Healthy Volunteers |
2014-05-01 |
2019-03-20 |
Treatments |
|
2014-004996-22 |
2014-004996-22 | P2 |
Completed |
Osteoarthritis, Knee |
2017-09-29 |
2022-03-13 |
Treatments |
|
NCT02611466 |
OAK | P2 |
Completed |
Osteoarthritis, Knee|Low Back Pain|Chronic Pain |
2017-08-28 |
2019-03-20 |